Какова цена за Poseida Therapeutics, Inc. (PSTX)

Цена за Poseida Therapeutics, Inc. (PSTX) Это $9.50

Какова рыночная капитализация для Poseida Therapeutics, Inc. (PSTX)

Рыночная капитализация для Poseida Therapeutics, Inc. (PSTX) Это $819.52M

Poseida Therapeutics, Inc. (PSTX) Операционная маржа

Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical firm established in 2014, is dedicated to advancing novel therapeutic solutions for conditions with significant unmet medical needs. Its pipeline prominently features several advanced cell therapies. For instance, P-PSMA-101, an autologous CAR-T cell therapy, is currently undergoing Phase I clinical trials for individuals battling metastatic castrate-resistant prostate cancer (mCRPC). Additionally, Poseida is progressing two other CAR-T candidates through Phase I: P-BCMA-ALLO1 targets relapsed/refractory multiple myeloma, while P-MUC1C-ALLO1 is designed to address a variety of solid tumors, such as breast, ovarian, and other epithelial-derived malignancies. The company is further exploring allogeneic (off-the-shelf) CAR-T approaches with candidates like P-CD19CD20-ALLO1, aimed at B cell malignancies and certain autoimmune conditions, and P-BCMACD19-ALLO1, which is in preclinical development for multiple myeloma. Another allogeneic CAR-T, P-PSMA-ALLO1, is also being developed for mCRPC. Beyond cell therapies, Poseida's portfolio includes clinical-stage liver-directed gene therapies, specifically P-OTC-101 and P-FVIII-101, alongside other exploratory allogeneic dual CAR candidates. Collaborative efforts include a research and licensing agreement with Takeda Pharmaceutical Company Limited.

Год	Операционная маржа	Изменить
2026 (TTM)	-200.15%	0.00%
2023	-200.15%	335.30%
2022	-45.98%	-89.84%
2021	-452.69%	0.00%
2020	0.00%	0.00%
2019	0.00%	0.00%
2018	0.00%	-100.00%
2017	-658.89%	1,081.23%
2016	-55.78%	0.00%

Год

Операционная маржа

Изменить

2026 (TTM)

-200.15%

0.00%

2023

-200.15%

335.30%

2022

-45.98%

-89.84%

2021

-452.69%

0.00%

2020

0.00%

2019

0.00%

2018

0.00%

-100.00%

2017

-658.89%

1,081.23%

2016

-55.78%

0.00%

Компания	Операционная маржа	Разница в операционной марже	Страна
Vertex Pharmaceuticals Incorporated VRTX.US	38.59%	-100.19%	US
Argenx SE ARGX.US	28.81%	-100.14%	NL
CSL Limited CSL.AX	25.72%	-100.13%	AU
Moderna, Inc. MRNA.US	-149.01%	-99.26%	US
Lonza Group AG LONN.SW	0.00%	-	CH

Компания

Операционная маржа

Разница в операционной марже

Страна